Cargando…
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here, using the novel BiXAb™ tetravalent format pl...
Autores principales: | Rabia, Emilia, Garambois, Véronique, Dhommée, Christine, Larbouret, Christel, Lajoie, Laurie, Buscail, Yoan, Jimenez-Dominguez, Gabriel, Choblet-Thery, Sylvie, Liaudet-Coopman, Emmanuelle, Cerutti, Martine, Jarlier, Marta, Ravel, Patrice, Gros, Laurent, Pirot, Nelly, Thibault, Gilles, Zhukovsky, Eugene A., Gérard, Pierre-Emmanuel, Pèlegrin, André, Colinge, Jacques, Chardès, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157173/ https://www.ncbi.nlm.nih.gov/pubmed/37153618 http://dx.doi.org/10.3389/fimmu.2023.1168444 |
Ejemplares similares
-
Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures
por: Larbouret, Christel, et al.
Publicado: (2021) -
The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation
por: Le Clorennec, Christophe, et al.
Publicado: (2016) -
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
por: Rabia, Emilia, et al.
Publicado: (2021) -
Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking
por: Lanotte, Romain, et al.
Publicado: (2020) -
Bispecific Antibodies for IFN-β Delivery to ErbB2(+) Tumors
por: Rybchenko, Vladislav S., et al.
Publicado: (2021)